サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1650419

鎌状赤血球症治療の世界市場：産業分析、規模、シェア、成長、動向、予測（2024年～2034年）

Sickle Cell Disease Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034

出版日
ページ情報
英文 213 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
鎌状赤血球症治療の世界市場：産業分析、規模、シェア、成長、動向、予測（2024年～2034年）
出版日: 2024年12月13日
発行: Transparency Market Research
ページ情報: 英文 213 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

鎌状赤血球症治療市場：調査範囲

TMRの調査レポート「鎌状赤血球症治療の世界市場」は、2024年～2034年の予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と機会についても調査しています。当レポートでは、2024年を基準年、2034年を予測年として、2018年～2034年の世界の鎌状赤血球症治療市場の収益と予測を提供しています。また、2024年～2034年の世界の鎌状赤血球症治療市場の複合年間成長率（CAGR%）も掲載しています。

本レポートは広範な調査を経て作成されています。1次調査では、アナリストが主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施しました。2次調査では、主要企業の製品資料、アニュアルレポート、プレスリリース、関連資料などを参照し、鎌状赤血球症治療市場を推察しました。

市場スナップショット
2023年の市場規模 27億米ドル
2034年の市場規模 177億米ドル
CAGR 18.5%

当レポートでは、世界の鎌状赤血球症治療市場の競合情勢について調査しています。世界の鎌状赤血球症治療市場で事業を展開する主要企業が特定され、各企業が様々な属性でプロファイルされています。企業概要、財務状況、最近の動向、SWOTが本レポートで紹介されている世界の鎌状赤血球症治療市場における企業の属性です。

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：世界市場

第4章 市場概要

  • イントロダクション
  • 概要
  • 市場力学
  • 世界の市場分析と予測（2020年～2034年）

第5章 主要洞察

  • 主要な業界イベント
  • PEST分析
  • パイプライン分析
  • 主要国・地域別の規制シナリオ
  • ポーターのファイブフォース分析
  • 主要国別の償還シナリオ
  • 価格分析
  • 製品/ブランド分析
  • 鎌状赤血球症の疫学
  • 技術的進歩
  • サプライチェーン分析
  • 市場のアンメットニーズ

第6章 世界の市場分析と予測：薬剤クラス別

  • イントロダクションと定義
  • 主な調査結果・発展
  • 市場金額予測：薬剤クラス別（2020年～2034年）
    • 代謝拮抗物質
    • アミノ酸
    • NSAIDs
    • モノクローナル抗体
    • その他
  • 市場の魅力分析：薬剤クラス別

第7章 世界の市場分析と予測：疾患別

  • イントロダクションと定義
  • 主な調査結果・発展
  • 市場金額予測：疾患別（2020年～2034年）
    • ヘモグロビンSS（HbSS）
    • ヘモグロビンSC（HbSC）
    • ヘモグロビン（HbS）ベータサラセミア
  • 市場の魅力分析：疾患別

第8章 世界の市場分析と予測：年齢別

  • イントロダクションと定義
  • 主な調査結果・発展
  • 市場金額予測：年齢別（2020年～2034年）
    • 小児
    • 成人
  • 市場の魅力分析：年齢別

第9章 世界の市場分析と予測：投与経路別

  • イントロダクションと定義
  • 主な調査結果・発展
  • 市場金額予測：投与経路別（2020年～2034年）
    • 経口
    • 非経口
  • 市場の魅力分析：投与経路別

第10章 世界の市場分析と予測：流通チャネル別

  • イントロダクションと定義
  • 主な調査結果・発展
  • 市場金額予測：流通チャネル別（2020年～2034年）
    • 院内薬局
    • 小売薬局
    • オンライン薬局
  • 市場の魅力分析：流通チャネル別

第11章 世界の市場分析と予測：地域別

  • 主な調査結果
  • 市場金額予測：地域別（2020年～2034年）
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場の魅力分析：地域別

第12章 北米の市場分析と予測

第13章 欧州の市場分析と予測

第14章 アジア太平洋の市場分析と予測

第15章 ラテンアメリカの市場分析と予測

第16章 中東・アフリカの市場分析と予測

第17章 競合情勢

  • 市場企業：競合マトリックス（企業階層と規模別）
  • 市場シェア分析：企業別（2023年）
  • 企業プロファイル
    • Bristol-Myers Squibb Company
    • Novartis AG
    • Emmaus Medical, Inc.
    • Bluebird bio Inc.
    • Pfizer Inc.
    • CRISPR Therapeutics
    • F. Hoffmann-La Roche AG
    • Vertex Pharmaceuticals Incorporated
    • Agios Pharmaceuticals, Inc.
    • GlycoMimetics
    • Graphite Bio, Inc.
    • Mylan N.V.
    • Teva Pharmaceutical Industries Ltd.
    • AstraZeneca
    • Hikma Pharmaceuticals PLC
    • Addmedica
図表

List of Tables

  • Table 01: Global Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, By Drug Class, 2020-2034
  • Table 02: Global Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, By Disease Type, 2020-2034
  • Table 03: Global Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, By Age-Group, 2020-2034
  • Table 04: Global Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, By Route of Administration, 2020-2034
  • Table 05: Global Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, By Distribution Channel, 2020-2034
  • Table 06: Global Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, by Region, 2020-2034
  • Table 07: North America - Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, by Country, 2020-2034
  • Table 08: North America Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, By Drug Class, 2020-2034
  • Table 09: North America - Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, by Disease Type, 2020-2034
  • Table 10: North America - Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, by Age-Group, 2020-2034
  • Table 11: North America - Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, by Route of Administration, 2020-2034
  • Table 12: North America - Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 13: Europe - Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 14: Europe Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, By Drug Class, 2020-2034
  • Table 15: Europe - Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, by Disease Type, 2020-2034
  • Table 16: Europe - Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, by Age-Group, 2020-2034
  • Table 17: Europe - Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, by Route of Administration, 2020-2034
  • Table 18: Europe - Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 19: Asia Pacific Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 20: Asia Pacific Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, By Drug Class, 2020-2034
  • Table 21: Asia Pacific - Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, by Disease Type, 2020-2034
  • Table 22: Asia Pacific - Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, by Age-Group, 2020-2034
  • Table 23: Asia Pacific - Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, by Route of Administration, 2020-2034
  • Table 24: Asia Pacific - Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 25: Latin America - Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 26: Latin America Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, By Drug Class, 2020-2034
  • Table 27: Latin America - Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, by Disease Type, 2020-2034
  • Table 28: Latin America - Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, by Age-Group, 2020-2034
  • Table 29: Latin America - Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, by Route of Administration, 2020-2034
  • Table 30: Latin America - Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 31: Middle East & Africa - Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 32: Middle East and Africa Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, By Drug Class, 2020-2034
  • Table 33: Middle East and Africa - Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, by Disease Type, 2020-2034
  • Table 34: Middle East and Africa - Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, by Age-Group, 2020-2034
  • Table 35: Middle East and Africa - Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, by Route of Administration, 2020-2034
  • Table 36: Middle East and Africa - Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2020-2034

List of Figures

  • Figure 01: Global Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast, 2020-2034
  • Figure 02: Global Sickle Cell Disease Treatment Market Value Share, by Drug Class, 2023
  • Figure 03: Global Sickle Cell Disease Treatment Market Value Share, by Disease Type, 2023
  • Figure 04: Global Sickle Cell Disease Treatment Market Value Share, by Age-Group, 2023
  • Figure 05: Global Sickle Cell Disease Treatment Market Value Share, by Route of Administration, 2023
  • Figure 06: Global Sickle Cell Disease Treatment Market Value Share, by End-user, 2023
  • Figure 07: Global Sickle Cell Disease Treatment Market Value (US$ Bn) Share Analysis, By Drug Class, 2023 and 2034
  • Figure 08: Global Sickle Cell Disease Treatment Market Share Analysis, By Drug Class, 2023
  • Figure 09: Global Sickle Cell Disease Treatment Market Share Analysis, By Drug Class, 2034
  • Figure 10: Global Sickle Cell Disease Treatment Market Attractiveness Analysis, By Drug Class, 2024-2034
  • Figure 11: Global Sickle Cell Disease Treatment Market Value (US$ Bn), by Antimetabolites, 2020-2034
  • Figure 12: Global Sickle Cell Disease Treatment Market Value Share Analysis, by Fixed Sickle Cell Disease Treatment, 2023 and 2034
  • Figure 13: Global Sickle Cell Disease Treatment Market Value (US$ Bn), by Amino Acids, 2020-2034
  • Figure 14: Global Sickle Cell Disease Treatment Market Value Share Analysis, by Amino Acids, 2023 and 2034
  • Figure 15: Global Sickle Cell Disease Treatment Market Value (US$ Bn), by NSAIDs, 2020-2034
  • Figure 16: Global Sickle Cell Disease Treatment Market Value Share Analysis, by NSAIDs, 2023 and 2034
  • Figure 17: Global Sickle Cell Disease Treatment Market Value (US$ Bn), by Monoclonal Antibodies, 2020-2034
  • Figure 18: Global Sickle Cell Disease Treatment Market Value Share Analysis, by Monoclonal Antibodies, 2023 and 2034
  • Figure 19: Global Sickle Cell Disease Treatment Market Value (US$ Bn), by Others, 2020-2034
  • Figure 20: Global Sickle Cell Disease Treatment Market Value Share Analysis, by Others, 2023 and 2034
  • Figure 21: Global Sickle Cell Disease Treatment Market Value (US$ Bn) Share Analysis, By Disease Type, 2023 and 2034
  • Figure 22: Global Sickle Cell Disease Treatment Market Share Analysis, By Disease Type, 2023
  • Figure 23: Global Sickle Cell Disease Treatment Market Share Analysis, By Disease Type, 2034
  • Figure 24: Global Sickle Cell Disease Treatment Market Attractiveness Analysis, By Disease Type, 2024-2034
  • Figure 25: Global Sickle Cell Disease Treatment Market Value (US$ Bn), by Hemoglobin SS (HbSS), 2020-2034
  • Figure 26: Global Sickle Cell Disease Treatment Market Value Share Analysis, by Hemoglobin SS (HbSS), 2023 and 2034
  • Figure 27: Global Sickle Cell Disease Treatment Market Value (US$ Bn), by Hemoglobin SC (HbSC) 2020-2034
  • Figure 28: Global Sickle Cell Disease Treatment Market Value Share Analysis, by Hemoglobin SC (HbSC), 2023 and 2034
  • Figure 29: Global Sickle Cell Disease Treatment Market Value (US$ Bn), by Hemoglobin (HbS) beta thalassemia, 2020-2034
  • Figure 30: Global Sickle Cell Disease Treatment Market Value Share Analysis, by Hemoglobin (HbS) beta thalassemia, 2023 and 2034
  • Figure 31: Global Sickle Cell Disease Treatment Market Value (US$ Bn) Share Analysis, By Age-Group, 2023 and 2034
  • Figure 32: Global Sickle Cell Disease Treatment Market Share Analysis, By Age-Group, 2023
  • Figure 33: Global Sickle Cell Disease Treatment Market Share Analysis, By Age-Group, 2034
  • Figure 34: Global Sickle Cell Disease Treatment Market Attractiveness Analysis, By Age-Group, 2024-2034
  • Figure 35: Global Sickle Cell Disease Treatment Market Value (US$ Bn), by Children, 2020-2034
  • Figure 36: Global Sickle Cell Disease Treatment Market Value Share Analysis, by Children, 2023 and 2034
  • Figure 37: Global Sickle Cell Disease Treatment Market Value (US$ Bn), by Adults, 2020-2034
  • Figure 38: Global Sickle Cell Disease Treatment Market Value Share Analysis, by Adults, 2023 and 2034
  • Figure 39: Global Sickle Cell Disease Treatment Market Value (US$ Bn) Share Analysis, By Route of Administration, 2023 and 2034
  • Figure 40: Global Sickle Cell Disease Treatment Market Share Analysis, By Route of Administration, 2023
  • Figure 41: Global Sickle Cell Disease Treatment Market Share Analysis, By Route of Administration, 2034
  • Figure 42: Global Sickle Cell Disease Treatment Market Attractiveness Analysis, By Route of Administration, 2024-2034
  • Figure 43: Global Sickle Cell Disease Treatment Market Value (US$ Bn), by Oral, 2020-2034
  • Figure 44: Global Sickle Cell Disease Treatment Market Value Share Analysis, by Oral, 2023 and 2034
  • Figure 45: Global Sickle Cell Disease Treatment Market Value (US$ Bn), by Parenteral, 2020-2034
  • Figure 46: Global Sickle Cell Disease Treatment Market Value Share Analysis, by Parenteral, 2023 and 2034
  • Figure 47: Global Sickle Cell Disease Treatment Market Value (US$ Bn) Share Analysis, By Distribution Channel, 2023 and 2034
  • Figure 48: Global Sickle Cell Disease Treatment Market Share Analysis, By Distribution Channel, 2023
  • Figure 49: Global Sickle Cell Disease Treatment Market Share Analysis, By Distribution Channel, 2034
  • Figure 50: Global Sickle Cell Disease Treatment Market Attractiveness Analysis, By Distribution Channel, 2024-2034
  • Figure 51: Global Sickle Cell Disease Treatment Market Value (US$ Bn), by Hospital Pharmacies, 2020-2034
  • Figure 52: Global Sickle Cell Disease Treatment Market Value Share Analysis, by Hospital Pharmacies, 2023 and 2034
  • Figure 53: Global Sickle Cell Disease Treatment Market Value (US$ Bn), by Retail Pharmacies, 2020-2034
  • Figure 54: Global Sickle Cell Disease Treatment Market Value Share Analysis, by Retail Pharmacies, 2023 and 2034
  • Figure 55: Global Sickle Cell Disease Treatment Market Value (US$ Bn), by Online Pharmacies, 2020-2034
  • Figure 56: Global Sickle Cell Disease Treatment Market Value Share Analysis, by Online Pharmacies, 2023 and 2034
  • Figure 57: Global Sickle Cell Disease Treatment Market Value Share Analysis, by Region, 2023 and 2034
  • Figure 58: Global Sickle Cell Disease Treatment Market Share Analysis, by Region, 2023
  • Figure 59: Global Sickle Cell Disease Treatment Market Share Analysis, by Region, 2034
  • Figure 60: Global Sickle Cell Disease Treatment Market Attractiveness Analysis, by Region, 2023-2034
  • Figure 61: North America - Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
  • Figure 62: North America - Sickle Cell Disease Treatment Market Value Share Analysis, by Country, 2023 and 2034
  • Figure 63: North America - Sickle Cell Disease Treatment Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 64: North America - Sickle Cell Disease Treatment Market Value (US$ Bn) Share Analysis, by Drug Class, 2023 and 2034
  • Figure 65: North America - Sickle Cell Disease Treatment Market Attractiveness Analysis, by Drug Class, 2024-2034
  • Figure 66: North America - Sickle Cell Disease Treatment Market Value (US$ Bn) Share Analysis, by Disease Type, 2023 and 2034
  • Figure 67: North America - Sickle Cell Disease Treatment Market Attractiveness Analysis, by Disease Type, 2024-2034
  • Figure 68: North America - Sickle Cell Disease Treatment Market Value (US$ Bn) Share Analysis, by Age-Group, 2023 and 2034
  • Figure 69: North America - Sickle Cell Disease Treatment Market Attractiveness Analysis, by Age-Group, 2024-2034
  • Figure 70: North America - Sickle Cell Disease Treatment Market Value (US$ Bn) Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 71: North America - Sickle Cell Disease Treatment Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 72: North America - Sickle Cell Disease Treatment Market Value (US$ Bn) Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 73: North America - Sickle Cell Disease Treatment Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 74: Europe - Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
  • Figure 75: Europe - Sickle Cell Disease Treatment Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 76: Europe - Sickle Cell Disease Treatment Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 77: Europe - Sickle Cell Disease Treatment Market Value (US$ Bn) Share Analysis, by Drug Class, 2023 and 2034
  • Figure 78: Europe - Sickle Cell Disease Treatment Market Attractiveness Analysis, by Drug Class, 2024-2034
  • Figure 79: Europe - Sickle Cell Disease Treatment Market Value (US$ Bn) Share Analysis, by Disease Type, 2023 and 2034
  • Figure 80: Europe - Sickle Cell Disease Treatment Market Attractiveness Analysis, by Disease Type, 2024-2034
  • Figure 81: Europe - Sickle Cell Disease Treatment Market Value (US$ Bn) Share Analysis, by Age-Group, 2023 and 2034
  • Figure 82: Europe - Sickle Cell Disease Treatment Market Attractiveness Analysis, by Age-Group, 2024-2034
  • Figure 83: Europe - Sickle Cell Disease Treatment Market Value (US$ Bn) Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 84: Europe - Sickle Cell Disease Treatment Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 85: Europe - Sickle Cell Disease Treatment Market Value (US$ Bn) Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 86: Europe - Sickle Cell Disease Treatment Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 87: Asia Pacific - Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
  • Figure 88: Asia Pacific - Sickle Cell Disease Treatment Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 89: Asia Pacific - Sickle Cell Disease Treatment Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 90: Asia Pacific - Sickle Cell Disease Treatment Market Value (US$ Bn) Share Analysis, by Drug Class, 2023 and 2034
  • Figure 91: Asia Pacific - Sickle Cell Disease Treatment Market Attractiveness Analysis, by Drug Class, 2024-2034
  • Figure 92: Asia Pacific - Sickle Cell Disease Treatment Market Value (US$ Bn) Share Analysis, by Disease Type, 2023 and 2034
  • Figure 93: Asia Pacific - Sickle Cell Disease Treatment Market Attractiveness Analysis, by Disease Type, 2024-2034
  • Figure 94: Asia Pacific - Sickle Cell Disease Treatment Market Value (US$ Bn) Share Analysis, by Age-Group, 2023 and 2034
  • Figure 95: Asia Pacific - Sickle Cell Disease Treatment Market Attractiveness Analysis, by Age-Group, 2024-2034
  • Figure 96: Asia Pacific - Sickle Cell Disease Treatment Market Value (US$ Bn) Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 97: Asia Pacific - Sickle Cell Disease Treatment Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 98: Asia Pacific - Sickle Cell Disease Treatment Market Value (US$ Bn) Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 99: Asia Pacific - Sickle Cell Disease Treatment Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 100: Latin America - Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
  • Figure 101: Latin America - Sickle Cell Disease Treatment Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 102: Latin America - Sickle Cell Disease Treatment Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 103: Latin America - Sickle Cell Disease Treatment Market Value (US$ Bn) Share Analysis, by Drug Class, 2023 and 2034
  • Figure 104: Latin America - Sickle Cell Disease Treatment Market Attractiveness Analysis, by Drug Class, 2024-2034
  • Figure 105: Latin America - Sickle Cell Disease Treatment Market Value (US$ Bn) Share Analysis, by Disease Type, 2023 and 2034
  • Figure 106: Latin America - Sickle Cell Disease Treatment Market Attractiveness Analysis, by Disease Type, 2024-2034
  • Figure 107: Latin America - Sickle Cell Disease Treatment Market Value (US$ Bn) Share Analysis, by Age-Group, 2023 and 2034
  • Figure 108: Latin America - Sickle Cell Disease Treatment Market Attractiveness Analysis, by Age-Group, 2024-2034
  • Figure 109: Latin America - Sickle Cell Disease Treatment Market Value (US$ Bn) Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 110: Latin America - Sickle Cell Disease Treatment Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 111: Latin America - Sickle Cell Disease Treatment Market Value (US$ Bn) Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 112: Latin America - Sickle Cell Disease Treatment Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 113: Middle East & Africa - Sickle Cell Disease Treatment Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
  • Figure 114: Middle East & Africa - Sickle Cell Disease Treatment Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 115: Middle East & Africa - Sickle Cell Disease Treatment Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 116: Middle East and Africa - Sickle Cell Disease Treatment Market Value (US$ Bn) Share Analysis, by Drug Class, 2023 and 2034
  • Figure 117: Middle East and Africa - Sickle Cell Disease Treatment Market Attractiveness Analysis, by Drug Class, 2024-2034
  • Figure 118: Middle East and Africa - Sickle Cell Disease Treatment Market Value (US$ Bn) Share Analysis, by Disease Type, 2023 and 2034
  • Figure 119: Middle East and Africa - Sickle Cell Disease Treatment Market Attractiveness Analysis, by Disease Type, 2024-2034
  • Figure 120: Middle East and Africa - Sickle Cell Disease Treatment Market Value (US$ Bn) Share Analysis, by Age-Group, 2023 and 2034
  • Figure 121: Middle East and Africa - Sickle Cell Disease Treatment Market Attractiveness Analysis, by Age-Group, 2024-2034
  • Figure 122: Middle East and Africa - Sickle Cell Disease Treatment Market Value (US$ Bn) Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 123: Middle East and Africa - Sickle Cell Disease Treatment Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 124: Middle East and Africa - Sickle Cell Disease Treatment Market Value (US$ Bn) Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 125: Middle East and Africa - Sickle Cell Disease Treatment Market Attractiveness Analysis, by Distribution Channel, 2024-2034
目次
Product Code: TMRGL65504

Sickle Cell Disease Treatment Market - Scope of Report

TMR's report on the global sickle cell disease treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global sickle cell disease treatment market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global sickle cell disease treatment market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the sickle cell disease treatment market.

Market Snapshot
Market Value in 2023US$ 2.7 Bn
Market Value in 2034US$ 17.7 Bn
CAGR18.5%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global sickle cell disease treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global sickle cell disease treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global sickle cell disease treatment market.

The report delves into the competitive landscape of the global sickle cell disease treatment market. Key players operating in the global sickle cell disease treatment market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global sickle cell disease treatment market profiled in this report.

Key Questions Answered in Global sickle cell disease treatment Market Report:

  • What is the sales/revenue generated by sickle cell disease treatment across all regions during the forecast period?
  • What are the opportunities in the global sickle cell disease treatment market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Sickle Cell Disease Treatment Market - Research Objectives and Research Approach

The comprehensive report on the global sickle cell disease treatment market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global sickle cell disease treatment market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global sickle cell disease treatment market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Sickle Cell Disease Treatment Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Sickle Cell Disease Treatment Market Analysis and Forecast, 2020-2034
    • 4.4.1. Market Revenue Projections (US$ Bn)

5. Key Insights

  • 5.1. Key Industry Events
  • 5.2. PEST Analysis
  • 5.3. Pipeline Analysis
  • 5.4. Regulatory Scenario by Key Countries/Regions
  • 5.5. PORTER's Five Forces Analysis
  • 5.6. Reimbursement Scenario by Key Countries
  • 5.7. Pricing Analysis
  • 5.8. Product/Brand Analysis
  • 5.9. Epidemiology of Sickle Cell Disease
  • 5.10. Technological Advancements
  • 5.11. Supply Chain Analysis
  • 5.12. Unmet Needs of the Market

6. Global Sickle Cell Disease Treatment Market Analysis and Forecast, by Drug Class

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Drug Class, 2020-2034
    • 6.3.1. Antimetabolites
    • 6.3.2. Amino Acids
    • 6.3.3. NSAIDs
    • 6.3.4. Monoclonal Antibodies
    • 6.3.5. Others
  • 6.4. Market Attractiveness Analysis, by Drug Class

7. Global Sickle Cell Disease Treatment Market Analysis and Forecast, by Disease Type

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Disease Type, 2020-2034
    • 7.3.1. Hemoglobin SS (HbSS)
    • 7.3.2. Hemoglobin SC (HbSC)
    • 7.3.3. Hemoglobin (HbS) beta thalassemia
  • 7.4. Market Attractiveness Analysis, by Disease Type

8. Global Sickle Cell Disease Treatment Market Analysis and Forecast, by Age-Group

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Age-Group, 2020-2034
    • 8.3.1. Children
    • 8.3.2. Adults
  • 8.4. Market Attractiveness Analysis, by Age-Group

9. Global Sickle Cell Disease Treatment Market Analysis and Forecast, by Route of Administration

  • 9.1. Introduction & Definition
  • 9.2. Key Findings/Developments
  • 9.3. Market Value Forecast, by Route of Administration, 2020-2034
    • 9.3.1. Oral
    • 9.3.2. Parenteral
  • 9.4. Market Attractiveness Analysis, by Route of Administration

10. Global Sickle Cell Disease Treatment Market Analysis and Forecast, by Distribution Channel

  • 10.1. Introduction & Definition
  • 10.2. Key Findings/Developments
  • 10.3. Market Value Forecast, by Distribution Channel, 2020-2034
    • 10.3.1. Hospital Pharmacies
    • 10.3.2. Retail Pharmacies
    • 10.3.3. Online Pharmacies
  • 10.4. Market Attractiveness Analysis, by Distribution Channel

11. Global Sickle Cell Disease Treatment Market Analysis and Forecast, by Region

  • 11.1. Key Findings
  • 11.2. Market Value Forecast, by Region, 2020-2034
    • 11.2.1. North America
    • 11.2.2. Europe
    • 11.2.3. Asia Pacific
    • 11.2.4. Latin America
    • 11.2.5. Middle East & Africa
  • 11.3. Market Attractiveness Analysis, by Region

12. North America Sickle Cell Disease Treatment Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Drug Class, 2020-2034
    • 12.2.1. Antimetabolites
    • 12.2.2. Amino Acids
    • 12.2.3. NSAIDs
    • 12.2.4. Monoclonal Antibodies
    • 12.2.5. Others
  • 12.3. Market Value Forecast, by Disease Type, 2020-2034
    • 12.3.1. Hemoglobin SS (HbSS)
    • 12.3.2. Hemoglobin SC (HbSC)
    • 12.3.3. Hemoglobin (HbS) beta thalassemia
  • 12.4. Market Value Forecast, by Age-Group, 2020-2034
    • 12.4.1. Children
    • 12.4.2. Adults
  • 12.5. Market Value Forecast, by Route of Administration, 2020-2034
    • 12.5.1. Oral
    • 12.5.2. Parenteral
  • 12.6. Market Value Forecast, by Distribution Channel, 2020-2034
    • 12.6.1. Hospital Pharmacies
    • 12.6.2. Retail Pharmacies
    • 12.6.3. Online Pharmacies
  • 12.7. Market Value Forecast, by Country, 2020-2034
    • 12.7.1. U.S.
    • 12.7.2. Canada
  • 12.8. Market Attractiveness Analysis
    • 12.8.1. By Drug Class
    • 12.8.2. By Disease Type
    • 12.8.3. By Age-Group
    • 12.8.4. By Route of Administration
    • 12.8.5. By Distribution Channel
    • 12.8.6. By Country

13. Europe Sickle Cell Disease Treatment Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Drug Class, 2020-2034
    • 13.2.1. Antimetabolites
    • 13.2.2. Amino Acids
    • 13.2.3. NSAIDs
    • 13.2.4. Monoclonal Antibodies
    • 13.2.5. Others
  • 13.3. Market Value Forecast, by Disease Type, 2020-2034
    • 13.3.1. Hemoglobin SS (HbSS)
    • 13.3.2. Hemoglobin SC (HbSC)
    • 13.3.3. Hemoglobin (HbS) beta thalassemia
  • 13.4. Market Value Forecast, by Age-Group, 2020-2034
    • 13.4.1. Children
    • 13.4.2. Adults
  • 13.5. Market Value Forecast, by Route of Administration, 2020-2034
    • 13.5.1. Oral
    • 13.5.2. Parenteral
  • 13.6. Market Value Forecast, by Distribution Channel, 2020-2034
    • 13.6.1. Hospital Pharmacies
    • 13.6.2. Retail Pharmacies
    • 13.6.3. Online Pharmacies
  • 13.7. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 13.7.1. Germany
    • 13.7.2. UK
    • 13.7.3. France
    • 13.7.4. Italy
    • 13.7.5. Spain
    • 13.7.6. Rest of Europe
  • 13.8. Market Attractiveness Analysis
    • 13.8.1. By Drug Class
    • 13.8.2. By Disease Type
    • 13.8.3. By Age-Group
    • 13.8.4. By Route of Administration
    • 13.8.5. By Distribution Channel
    • 13.8.6. By Country/Sub-region

14. Asia Pacific Sickle Cell Disease Treatment Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Drug Class, 2020-2034
    • 14.2.1. Antimetabolites
    • 14.2.2. Amino Acids
    • 14.2.3. NSAIDs
    • 14.2.4. Monoclonal Antibodies
    • 14.2.5. Others
  • 14.3. Market Value Forecast, by Disease Type, 2020-2034
    • 14.3.1. Hemoglobin SS (HbSS)
    • 14.3.2. Hemoglobin SC (HbSC)
    • 14.3.3. Hemoglobin (HbS) beta thalassemia
  • 14.4. Market Value Forecast, by Age-Group, 2020-2034
    • 14.4.1. Children
    • 14.4.2. Adults
  • 14.5. Market Value Forecast, by Route of Administration, 2020-2034
    • 14.5.1. Oral
    • 14.5.2. Parenteral
  • 14.6. Market Value Forecast, by Distribution Channel, 2020-2034
    • 14.6.1. Hospital Pharmacies
    • 14.6.2. Retail Pharmacies
    • 14.6.3. Online Pharmacies
  • 14.7. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 14.7.1. China
    • 14.7.2. Japan
    • 14.7.3. India
    • 14.7.4. Australia & New Zealand
    • 14.7.5. Rest of Asia Pacific
  • 14.8. Market Attractiveness Analysis
    • 14.8.1. By Drug Class
    • 14.8.2. By Disease Type
    • 14.8.3. By Age-Group
    • 14.8.4. By Route of Administration
    • 14.8.5. By Distribution Channel
    • 14.8.6. By Country/Sub-region

15. Latin America Sickle Cell Disease Treatment Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Drug Class, 2020-2034
    • 15.2.1. Antimetabolites
    • 15.2.2. Amino Acids
    • 15.2.3. NSAIDs
    • 15.2.4. Monoclonal Antibodies
    • 15.2.5. Others
  • 15.3. Market Value Forecast, by Disease Type, 2020-2034
    • 15.3.1. Hemoglobin SS (HbSS)
    • 15.3.2. Hemoglobin SC (HbSC)
    • 15.3.3. Hemoglobin (HbS) beta thalassemia
  • 15.4. Market Value Forecast, by Age-Group, 2020-2034
    • 15.4.1. Children
    • 15.4.2. Adults
  • 15.5. Market Value Forecast, by Route of Administration, 2020-2034
    • 15.5.1. Oral
    • 15.5.2. Parenteral
  • 15.6. Market Value Forecast, by Distribution Channel, 2020-2034
    • 15.6.1. Hospital Pharmacies
    • 15.6.2. Retail Pharmacies
    • 15.6.3. Online Pharmacies
  • 15.7. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 15.7.1. Brazil
    • 15.7.2. Mexico
    • 15.7.3. Rest of Latin America
  • 15.8. Market Attractiveness Analysis
    • 15.8.1. By Drug Class
    • 15.8.2. By Disease Type
    • 15.8.3. By Age-Group
    • 15.8.4. By Route of Administration
    • 15.8.5. By Distribution Channel
    • 15.8.6. By Country/Sub-region

16. Middle East & Africa Sickle Cell Disease Treatment Market Analysis and Forecast

  • 16.1. Introduction
    • 16.1.1. Key Findings
  • 16.2. Market Value Forecast, by Drug Class, 2020-2034
    • 16.2.1. Antimetabolites
    • 16.2.2. Amino Acids
    • 16.2.3. NSAIDs
    • 16.2.4. Monoclonal Antibodies
    • 16.2.5. Others
  • 16.3. Market Value Forecast, by Disease Type, 2020-2034
    • 16.3.1. Hemoglobin SS (HbSS)
    • 16.3.2. Hemoglobin SC (HbSC)
    • 16.3.3. Hemoglobin (HbS) beta thalassemia
  • 16.4. Market Value Forecast, by Age-Group, 2020-2034
    • 16.4.1. Children
    • 16.4.2. Adults
  • 16.5. Market Value Forecast, by Route of Administration, 2020-2034
    • 16.5.1. Oral
    • 16.5.2. Parenteral
  • 16.6. Market Value Forecast, by Distribution Channel, 2020-2034
    • 16.6.1. Hospital Pharmacies
    • 16.6.2. Retail Pharmacies
    • 16.6.3. Online Pharmacies
  • 16.7. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 16.7.1. GCC Countries
    • 16.7.2. South Africa
    • 16.7.3. Rest of Middle East & Africa
  • 16.8. Market Attractiveness Analysis
    • 16.8.1. By Drug Class
    • 16.8.2. By Disease Type
    • 16.8.3. By Age-Group
    • 16.8.4. By Route of Administration
    • 16.8.5. By Distribution Channel
    • 16.8.6. By Country/Sub-region

17. Competition Landscape

  • 17.1. Market Player - Competition Matrix (By Tier and Size of companies)
  • 17.2. Market Share Analysis, by Company (2023)
  • 17.3. Company Profiles
    • 17.3.1. Bristol-Myers Squibb Company
      • 17.3.1.1. Company Overview
      • 17.3.1.2. Financial Overview
      • 17.3.1.3. Product Portfolio
      • 17.3.1.4. Business Strategies
      • 17.3.1.5. Recent Developments
    • 17.3.2. Novartis AG
      • 17.3.2.1. Company Overview
      • 17.3.2.2. Financial Overview
      • 17.3.2.3. Product Portfolio
      • 17.3.2.4. Business Strategies
      • 17.3.2.5. Recent Developments
    • 17.3.3. Emmaus Medical, Inc.
      • 17.3.3.1. Company Overview
      • 17.3.3.2. Financial Overview
      • 17.3.3.3. Product Portfolio
      • 17.3.3.4. Business Strategies
      • 17.3.3.5. Recent Developments
    • 17.3.4. Bluebird bio Inc.
      • 17.3.4.1. Company Overview
      • 17.3.4.2. Financial Overview
      • 17.3.4.3. Product Portfolio
      • 17.3.4.4. Business Strategies
      • 17.3.4.5. Recent Developments
    • 17.3.5. Pfizer Inc.
      • 17.3.5.1. Company Overview
      • 17.3.5.2. Financial Overview
      • 17.3.5.3. Product Portfolio
      • 17.3.5.4. Business Strategies
      • 17.3.5.5. Recent Developments
    • 17.3.6. CRISPR Therapeutics
      • 17.3.6.1. Company Overview
      • 17.3.6.2. Financial Overview
      • 17.3.6.3. Product Portfolio
      • 17.3.6.4. Business Strategies
      • 17.3.6.5. Recent Developments
    • 17.3.7. F. Hoffmann-La Roche AG
      • 17.3.7.1. Company Overview
      • 17.3.7.2. Financial Overview
      • 17.3.7.3. Product Portfolio
      • 17.3.7.4. Business Strategies
      • 17.3.7.5. Recent Developments
    • 17.3.8. Vertex Pharmaceuticals Incorporated
      • 17.3.8.1. Company Overview
      • 17.3.8.2. Financial Overview
      • 17.3.8.3. Product Portfolio
      • 17.3.8.4. Business Strategies
      • 17.3.8.5. Recent Developments
    • 17.3.9. Agios Pharmaceuticals, Inc.
      • 17.3.9.1. Company Overview
      • 17.3.9.2. Financial Overview
      • 17.3.9.3. Product Portfolio
      • 17.3.9.4. Business Strategies
      • 17.3.9.5. Recent Developments
    • 17.3.10. GlycoMimetics
      • 17.3.10.1. Company Overview
      • 17.3.10.2. Financial Overview
      • 17.3.10.3. Product Portfolio
      • 17.3.10.4. Business Strategies
      • 17.3.10.5. Recent Developments
    • 17.3.11. Graphite Bio, Inc.
      • 17.3.11.1. Company Overview
      • 17.3.11.2. Financial Overview
      • 17.3.11.3. Product Portfolio
      • 17.3.11.4. Business Strategies
      • 17.3.11.5. Recent Developments
    • 17.3.12. Mylan N.V.
      • 17.3.12.1. Company Overview
      • 17.3.12.2. Financial Overview
      • 17.3.12.3. Product Portfolio
      • 17.3.12.4. Business Strategies
      • 17.3.12.5. Recent Developments
    • 17.3.13. Teva Pharmaceutical Industries Ltd.
      • 17.3.13.1. Company Overview
      • 17.3.13.2. Financial Overview
      • 17.3.13.3. Product Portfolio
      • 17.3.13.4. Business Strategies
      • 17.3.13.5. Recent Developments
    • 17.3.14. AstraZeneca
      • 17.3.14.1. Company Overview
      • 17.3.14.2. Financial Overview
      • 17.3.14.3. Product Portfolio
      • 17.3.14.4. Business Strategies
      • 17.3.14.5. Recent Developments
    • 17.3.15. Hikma Pharmaceuticals PLC
      • 17.3.15.1. Company Overview
      • 17.3.15.2. Financial Overview
      • 17.3.15.3. Product Portfolio
      • 17.3.15.4. Business Strategies
      • 17.3.15.5. Recent Developments
    • 17.3.16. Addmedica
      • 17.3.16.1. Company Overview
      • 17.3.16.2. Financial Overview
      • 17.3.16.3. Product Portfolio
      • 17.3.16.4. Business Strategies
      • 17.3.16.5. Recent Developments